Instrument Inactif

Communiqués Five Prime Therapeutics, Inc.

Actions

FPRX

US33830X1046

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS	05/08/22	AQ
Amgen : Successfully Completes Acquisition Of Five Prime Therapeutics	19/04/21	AQ
FIVE PRIME THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	16/04/21	AQ
Amgen : Successfully Completes Acquisition Of Five Prime Therapeutics	16/04/21	PR
FIVE PRIME THERAPEUTICS, INC. : Other Events (form 8-K)	15/04/21	AQ
Five Prime Therapeutics : Annual Report (SEC Filing - 10-K)	22/03/21	PU
FIVE PRIME THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	22/03/21	AQ
FIVE PRIME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Five Prime Therapeutics - FPRX	12/03/21	BU
Five Prime Therapeutics : Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call	09/03/21	BU
FIVE PRIME THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	04/03/21	AQ
Amgen : To Acquire Five Prime Therapeutics For $1.9 Billion in Cash	04/03/21	PR
Five Prime Therapeutics : Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call	02/03/21	BU
Five Prime Therapeutics : to Participate in the Cowen 41st Annual Health Care Conference	26/02/21	BU
Five Prime Therapeutics : Corporate Overview February 2020	25/02/21	PU
Five Prime Therapeutics : to Participate in the SVB Leerink 10th Annual Global Healthcare Conference	23/02/21	BU
Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day	05/02/21	BU
FIVE PRIME THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)	15/01/21	AQ
Five Prime Therapeutics : Bema P2 Data Presentation KOL Event	15/01/21	PU
FIVE PRIME THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	15/01/21	AQ
Five Prime Therapeutics : Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers	15/01/21	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Five Prime Therapeutics, Inc.

Actions

FPRX

US33830X1046

Communiqués

Filtres